Low-dose weekly paclitaxel as second-line treatment for advanced non-small cell lung cancer: a phase II study.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Japanese Journal of Clinical Oncology

• Publication date

  2002-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/JJCO/HYF098PMID 12499416
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines

  2004influential reference
• Weekly paclitaxel in advanced non-small cell lung cancer.

  2001cited by this paper
• Single-agent versus combination chemotherapy in advanced non-small cell lung cancer (NSCLC): A CALGB randomized trial of efficacy, quality of life, and cost-effectiveness

  2001cited by this paper
• Activity of docetaxel in platinum-treated non-small-cell lung cancer: results of a phase II multicenter trial.

  2000cited by this paper
• Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer: a review.

  2000cited by this paper
• Second-line chemotherapy for recurrent non-small cell lung cancer: do new agents make a difference?

  2000influential reference
• Second-line (SL) weekly paclitaxel (P) in patients (pts) with advanced non-small cell lung cancer (NSCLC) failing first-line (FL) carboplatin/paclitaxel (C/P)

  2000cited by this paper
• Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial.

  2000cited by this paper
• Paclitaxel (175 mg/m2) plus carboplatin (6 AUC) versus paclitaxel (225 mg/m2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): a multicenter randomized trial. Hellenic Cooperative Oncology Group (HeCOG).

  2000cited by this paper
• Docetaxel and granulocyte colony-stimulating factor in patients with advanced non-small-cell lung cancer previously treated with platinum-based chemotherapy: a multicenter phase II trial

  1999cited by this paper
• Single-agent gemcitabine in pretreated patients with non-small-cell lung cancer: results of an Argentinean multicentre phase II trial

  1999cited by this paper
• Single-agent paclitaxel in the treatment of advanced non-small cell lung cancer.

  1999cited by this paper
• Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: A phase II trial.

  1999cited by this paper
• Phase I trial of weekly paclitaxel in advanced lung cancer.

  1998cited by this paper
• Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer.

  1998cited by this paper
• Weekly paclitaxel in patients with advanced lung cancer: preliminary data from a phase II trial.

  1997cited by this paper
• Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death.

  1996cited by this paper
• Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials

  1996cited by this paper
• Phase I study with a weekly 1 h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer.

  1996cited by this paper
• Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer.

  1995cited by this paper
• Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group.

  1995cited by this paper
• Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature.

  1994cited by this paper
• Polychemotherapy in advanced non small cell lung cancer: a meta-analysis.

  1993cited by this paper
• Optimal two-stage designs for phase II clinical trials.

  1989cited by this paper
• Reporting results of cancer treatment

  1981cited by this paper
• WHO Handbook for Reporting Results of Cancer Treatment

  1980cited by this paper

• A graphSAGE discovers synergistic combinations of Gefitinib, paclitaxel, and Icotinib for Lung adenocarcinoma management by targeting human genes and proteins: the RAIN protocol

  2024cites this paper
• Doxorubicin induced epigenetic regulation of dendritic cell maturation in association with T cell activation facilitates tumor protective immune response in non-small cell lung cancer (NSCLC).

  2023cites this paper
• New Trends and Future Opportunities in the Enzymatic Formation of C−C, C−N, and C−O bonds

  2021cites this paper
• Nab-paclitaxel Monotherapy for Relapsed Small Cell Lung Cancer: Retrospective Analysis and Review

  2020cites this paper
• Autophagy inhibition with chloroquine reverts paclitaxel resistance and attenuates metastatic potential in human nonsmall lung adenocarcinoma A549 cells via ROS mediated modulation of β-catenin pathway

  2019cites this paper
• Circulating immune biomarkers as predictors of the response to pembrolizumab and weekly low dose carboplatin and paclitaxel in NSCLC and poor PS: An interim analysis.

  2018cites this paper
• Paclitaxel resistance development is associated with biphasic changes in reactive oxygen species, mitochondrial membrane potential and autophagy with elevated energy production capacity in lung cancer cells: A chronological study

  2017cites this paper
• Weekly paclitaxel after first-line failure in patients with advanced non-small-cell lung cancer: everyday clinical practice in a single centre

  2017cites this paper
• Carcinome bronchique non à petites cellules : quelle chimiothérapie de rattrapage ?

  2014cites this paper
• Efficacy and safety of metronomic administration of paclitaxel for advanced recurrent non-small-cell lung cancer.

  2013cites this paper
• Epigenetic and Post-Translational Mechanisms in Pain: MicroRNA and Phosphorylation

  2012cites this paper
• Second-line weekly paclitaxel in resistant or relapsed non-small cell lung cancer treated with docetaxel and carboplatin: a multi-center phase II study.

  2010cites this paper
• A phase II trial of weekly chemotherapy with paclitaxel plus gemcitabine as a first-line treatment in advanced non-small-cell lung cancer

  2009cites this paper
• First- and second-line therapy for advanced nonsmall cell lung cancer

  2009cites this paper
• Phase I/II Study of a 3 Weekly Oral Taxane (DJ-927) in Patients with Recurrent, Advanced Non-small Cell Lung Cancer

  2008cites this paper
• Phase II study of weekly chemotherapy with paclitaxel and gemcitabine as second-line treatment for advanced non-small cell lung cancer after treatment with platinum-based chemotherapy

  2007cites this paper
• Second-line paclitaxel in non-small cell lung cancer initially treated with cisplatin: a study by the European Lung Cancer Working Party

  2007influential citation
• Measurement and impact of co-morbidity in elderly patients with advanced non-small cell lung cancer treated with chemotherapy. A phase II study of weekly paclitaxel

  2007cites this paper
• Second-Line Chemotherapy for Non-Small-Cell Lung Cancer

  2006cites this paper
• Phase II study: combination of carboplatin and paclitaxel as second-line treatment in metastatic non-small-cell lung cancer

  2006cites this paper
• Is the Importance of Achieving Stable Disease Different between Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Cytotoxic Agents in the Second-Line Setting for Advanced Non-small Cell Lung Cancer?

  2006cites this paper
• Second-line treatment for advanced non-small cell lung cancer: a systematic review.

  2006cites this paper
• Current approaches in chemotherapy of advanced and metastatic non-small cell lung cancer (NSCLC).

  2005cites this paper
• Carboplatin and weekly paclitaxel in non-small cell lung cancer patients unfit for or pretreated with chemotherapy.

  2005cites this paper
• Lung cancer.

  2005cites this paper
• Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel.

  2005cites this paper
• Perspectives on salvage therapy for non-small-cell lung cancer.

  2005cites this paper
• Weekly paclitaxel as second/third-line treatment in advanced non-small cell lung cancer patients: efficacy and tolerability.

  2005cites this paper
• Phase II Study of Weekly Paclitaxel in Patients with Non-Small Cell Lung Cancer Who Have Failed Previous Treatments

  2004cites this paper
• Second-line weekly paclitaxel in patients with inoperable non-small cell lung cancer who fail combination chemotherapy with cisplatin.

  2004influential citation
• Chemotherapy in stage-IV NSCLC.

  2004cites this paper
• Gefitinib: a new antineoplastic for advanced non-small-cell lung cancer.

  2004cites this paper
• Phase II study of weekly paclitaxel as second-line therapy in patients with advanced non-small cell lung cancer.

  2004cites this paper
• Chemotherapy of Two Cases of Recurrent or Residual Non-small Cell Lung Cancer Responding Completely to Paclitaxel

  2003cites this paper
• Prospective randomised phase II study of docetaxel versus paclitaxel administered weekly in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

  2003cites this paper
• Taxol ® : dix ans après…

  2002cites this paper